Related Experiment Video
Updated: Dec 27, 2025
Author Spotlight: Advancements in Refractive Surgical Correction for Presbyopia and Exploring Postoperative Visual Acuity
Published on: September 20, 2024
Human allograft refractive lenticular implantation for high hyperopiccorrection
Majid Moshirfar1, Grant C Hopping, Anisha N Somani
1From the Department of Ophthalmology and Visual Sciences, John A. Moran Eye Center, University of Utah School of Medicine (Moshirfar), Salt Lake City, Utah Lions Eye Bank (Moshirfar), Murray, Hoopes Durrie Rivera Research Center, Hoopes Vision (Moshirfar, Linn, Ronquillo, Hoopes), Draper, Utah, McGovern Medical School, University of Texas Health Science Center (Hopping, Somani, Vaidyanathan, Liu), Houston, Texas, and Virginia Commonwealth University School of Medicine (Barnes), Richmond, USA.
Lenticule Intrastromal Keratoplasty (LIKE) offers a new surgical option for correcting severe hyperopia (farsightedness). This study details the first US intrastromal implantation of an allograft lenticule, showing LIKE
Area of Science:
- Ophthalmology
- Refractive Surgery
- Corneal Surgery
Background:
- Hyperopia, a common refractive error, presents challenges for traditional laser surgeries in severe cases (≥+5.0 D) due to high regression rates.
- Existing refractive surgery methods like LASIK and PRK have limitations for correcting high hyperopia.
Observation:
- This study reports the first intrastromal implantation of an allograft lenticule in the United States for primary hyperopia correction.
- The procedure, Lenticule Intrastromal Keratoplasty (LIKE), was performed on a patient with high hyperopia.
Findings:
- Lenticule Intrastromal Keratoplasty (LIKE) demonstrates potential effectiveness in correcting high hyperopia.
- The study discusses the mechanisms for refractive correction and complications encountered, such as epithelial ingrowth and flap necrosis.
Implications:
- LIKE may offer a viable alternative surgical treatment for patients with significant hyperopia.
- Further research is needed to fully establish LIKE's efficacy and safety profile for widespread clinical use.
